EXHIBIT 10.21 CONFIDENTIAL INFORMATION HAS BEEN OMITTED PURSUANT TO RULE 406 UNDER THE SECURITIES ACT AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. THE LOCATIONS OF THE OMITTED INFORMATION HAVE BEEN INDICATED WITH...Development Collaboration Agreement • October 28th, 1999 • Plug Power Inc • Electrical industrial apparatus • England
AMENDMENT NO. 2 TO REVIVE AND AMEND THE DEVELOPMENT COLLABORATION AGREEMENTDevelopment Collaboration Agreement • February 28th, 2022 • iRhythm Technologies, Inc. • Surgical & medical instruments & apparatus
This AMENDMENT NO. 2 TO REVIVE AND AMEND THE DEVELOPMENT AND COLLABORATION AGREEMENT (“Amendment”) is entered into by Verily Life Sciences LLC whose principal place of business is at 269 East Grand Avenue, South San Francisco, California 94080 USA (“VLS”), Verily Ireland Limited, organized under the laws of Ireland and having a principal place of business at 70 Sir John Rogerson’s Quay, Dublin 2, Ireland (“VIL,” and together with VLS, “Verily”), and iRhythm Technologies, Inc., organized under the laws of Delaware and having a principal place of business at 699 8th Street, Suite 600, San Francisco, CA 94103 (“IRTC”).
AMENDMENT NO. 1 TO DEVELOPMENT COLLABORATION AGREEMENTDevelopment Collaboration Agreement • February 28th, 2022 • iRhythm Technologies, Inc. • Surgical & medical instruments & apparatus
This amendment to the Development and Collaboration Agreement (“Amendment”) is entered into by Verily Life Sciences LLC whose principal place of business is at 269 East Grand Avenue, South San Francisco, California 94080 USA (“VLS”), Verily Ireland Limited, organized under the laws of Ireland and having a principal place of business at 70 Sir John Rogerson’s Quay, Dublin 2, Ireland (“VIL,” and together with VLS, “Verily”), and iRhythm Technologies, Inc., organized under the laws of Delaware and having a principal place of business at 699 8th Street, Suite 600, San Francisco, CA 94103 (“IRTC”).
CANCER EARLY DETECTION ALGORITHM DEVELOPMENT COLLABORATION AGREEMENTDevelopment Collaboration Agreement • June 22nd, 2018 • 20/20 GeneSystems, Inc. • Services-testing laboratories • Maryland
THIS DEVELOPMENT COLLABORATION AGREEMENT (this “Agreement”) having an effective date of February 26, 2016 (“Effective Date”), is entered into by and between National Foundation for Cancer Research, Inc., 4600 East West Highway, Suite 525, Bethesda, Maryland 20814 (“NFCR”) and 20/20 GenesyStems, Inc., 9430 Key West Avenue, Rockville, MD 20850 (“20/20”).
Certain identified information has been excluded from this exhibit because it is both not material and would likely cause competitive harm to the registrant if publicly disclosed*** DEVELOPMENT COLLABORATION AGREEMENT by and among VERILY LIFE SCIENCES...Development Collaboration Agreement • December 23rd, 2019 • iRhythm Technologies, Inc. • Surgical & medical instruments & apparatus • California
This Development Collaboration Agreement (together with all schedules and exhibits, the “Agreement”), is entered into as of the date of last signature below (the “Effective Date”) by and among Verily Life Sciences LLC, organized under the laws of Delaware and having a principal place of business at 269 East Grand Avenue, South San Francisco, CA 94080 (“VLS”), Verily Ireland Limited, organized under the laws of Ireland and having a principal place of business at 70 Sir John Rogerson’s Quay, Dublin 2, Ireland (“VIL,” and together with VLS, “Verily”), and iRhythm Technologies, Inc., organized under the laws of Delaware and having a principal place of business at 650 Townsend Street, Suite 500, San Francisco, CA 94103 (“IRTC”). Each of Verily and IRTC are referred to as a “Party” and together the “Parties.”
AMENDMENT 2 TO DEVELOPMENT COLLABORATION AGREEMENTDevelopment Collaboration Agreement • October 17th, 2023 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations
ContractDevelopment Collaboration Agreement • November 21st, 2016 • Moleculin Biotech, Inc. • Pharmaceutical preparations • Texas
This DEVELOPMENT COLLABORATION Agreement (the "Agreement") dated as of September 30, 2016 (the "Effective Date") is entered into by and between Moleculin Biotech, Inc. ("MBI"), a Delaware corporation, having a business address of 2575 West Bellfort Dr., Suite 333, Houston, TX 77054 and Dennin Sp. z o. o. a limited liability company having a principal place of business located at PL-00-116 Warszawa, ul. Switokrzyska 30/63, Poland ("Dermin"). MBI and Dermin are sometimes referred to herein individually as a "Party" and collectively as the "Parties."
CONFIDENTIAL TREATMENT REQUESTED CONFIDENTIAL PORTIONS REDACTEDDevelopment Collaboration Agreement • November 10th, 2021 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations
This DEVELOPMENT COLLABORATION Agreement (this “Agreement”) is entered into on October 8, 2021 (the “Effective Date”), by and between LIXTE BIOTECHNOLOGY HOLDINGS, INC. (“Lixte”), with its office and place of business at 680 E Colorado Blvd., Suite 180, Pasadena, CA 91101 and STICHTING HET NEDERLANDS KANKER INSTITUUT – ANTONI VAN LEEUWENHOEK ZIEKENHUIS, a foundation incorporated under the laws of The Netherlands, with its registered office at Plesmanlaan 121, 1066 CX Amsterdam (“NKI-AVL” or “Institution”) and STICHTING ONCODE INSTITUTE, a foundation incorporated under the laws of The Netherlands, with its registered office at Jaarbeursplein 6, 3521AL, Utrecht, and registered with the chamber of commerce with number 69303010 (“Oncode”). Each of Lixte, NKI-AVL and Oncode are referred to as a “Party” and together as, the “Parties.”
BACKGROUNDDevelopment Collaboration Agreement • December 1st, 2003 • Dynavax Technologies Corp • Pharmaceutical preparations • California
DATED March 15, 2019 DEVELOPMENT COLLABORATION AGREEMENT between NIU TECHNOLOGIES and VOLKSWAGEN AKTIENGESELLSCHAFTDevelopment Collaboration Agreement • April 25th, 2019 • Niu Technologies • Motor vehicles & passenger car bodies • England and Wales
